Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 21, 2019

Lilly reports negative results from cancer drug trial

Eli Lilly and Company has reported negative results from the Announce trial, a Phase lll study of Lartruvo (olaratumab) in combination with doxorubicin to treat patients with advanced or metastatic soft tissue sarcoma (STS), a rare type of cancer. 

Eli Lilly and Company has reported negative results from the Phase III Announce trial of lartruvo (olaratumab) in combination with doxorubicin to treat patients with advanced or metastatic soft tissue sarcoma (STS), a rare type of cancer.

The trial failed to meet its primary endpoint of overall survival (OS) in the complete study population or in the leiomyosarcoma (LMS) sub-population.

Results also showed no difference in the rate of survival between the study arms for either population. The trial did not confirm the clinical benefit of the study drug combination.

Lartruvo was found to be well tolerated with no new safety signals during the trial.

“Lilly was surprised and disappointed that lartruvo did not improve survival for patients with advanced soft tissue sarcoma in this study.”

Lilly now plans to suspend promotion of lartruvo, a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody.

Lartruvo is being studied in combination with gemcitabine and docetaxel.in a global, randomised, double-blind, placebo-controlled Phase II trial in advanced STS.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Eli Lilly and Company Oncology president Anne White said: “Lilly was surprised and disappointed that lartruvo did not improve survival for patients with advanced soft tissue sarcoma in this study.

“Lilly is committed to helping people who have soft tissue sarcoma and we will carefully study the detailed data in an effort to better understand the different results between the two trials.”

Investigators examined lartruvo in combination with doxorubicin, followed by lartruvo monotherapy, against doxorubicin plus placebo followed by placebo.

Key secondary endpoints of the trial comprise safety, progression-free survival, objective response rate, and patient-reported outcomes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU